Table 2.
Serum Markers, Antiplatelet Therapy, and Late Lumen Loss at 6‐ and 18‐Month Follow‐Up
| 6 Months | 18 Months | P Value | |
|---|---|---|---|
| Follow‐up period, d | 191 ± 16 | 556 ± 22 | |
| Serum markers | |||
| HbA1c (%) | 6.0 ± 1.3 | 6.0 ± 1.0 | 0.982 |
| LDL cholesterol (mg/dL) | 95 ± 26 | 83 ± 19 | 0.005 |
| HDL cholesterol (mg/dL) | 45 ± 10 | 44 ± 11 | 0.373 |
| High‐sensitivity CRP (mg/dL) | 0.12 ± 0.07 | 0.32 ± 0.79 | 0.319 |
| Estimated GFR (mL/min/1.73 m2) | 88 ± 26 | 92 ± 30 | 0.319 |
| Dual antiplatelet therapy at follow‐up | 19 (100) | 7 (37) | <0.001 |
| Late lumen loss (mm) | 0.33 ± 0.25 | 0.29 ± 0.24 | 0.490 |
Abbreviations: CRP, C‐reactive protein; GFR, glomerular filtration rate; HbA1c, glycated hemoglobin; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein.
Data are presented as mean ± SD or n (%).